Keqian Biology(SH:688526)2025-02-26 09:15Financial Performance - In 2024, the company achieved total operating revenue of RMB 947.87 million, a decrease of 10.92% compared to the previous year[4] - The net profit attributable to shareholders was RMB 375.08 million, down 5.27% year-on-year[4] - Basic earnings per share decreased to RMB 0.80, down 5.88% from RMB 0.85 in the previous year[4] Assets and Equity - The company's total assets at the end of the reporting period were RMB 4.49 billion, a decrease of 3.96% from the beginning of the year[5] - Shareholders' equity attributable to the company increased by 2.56% to RMB 3.93 billion[5] Market Conditions - The company is facing intensified market competition, leading to a decline in revenue and net profit[6] - As of the end of 2024, the national pig inventory was 427.43 million heads, a decrease of 1.6% year-on-year[6] Research and Development - The company is increasing its R&D efforts to accelerate new product development and enhance market competitiveness[6] Financial Reporting - The financial data presented are preliminary and unaudited, with final figures to be disclosed in the annual report[9] - Investors are advised to be aware of potential risks related to the preliminary financial data[9]